预约演示
更新于：2025-01-08
Glycopyrrolate
格隆溴铵
更新于：2025-01-08
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1961-08-11), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C19H28BrNO3 |
InChIKeyVPNYRYCIDCJBOM-HPUDQCTASA-M |
CAS号51186-83-5 |
关联
221
项与 格隆溴铵 相关的临床试验CTRI/2024/10/075606
A randomized, double-blind, double-dummy clinical trial to assess the efficacy and safety of fixed dose combination of Glycopyrronium 25 µg, Formoterol Fumarate 20 µg, Budesonide 500 µg Inhalation Suspension (for nebulization) in comparison with fixed dose combination of Formoterol Fumarate Dihydrate 5 µg, Glycopyrronium 7.2 µg and Budesonide 160 µg pressured inhalation suspension in patients with chronic obstructive pulmonary disease. - NIL
NCT06545500
A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects with COPD
CTRI/2024/06/068599
Comparing the efficacy of 3% NACL with pressure dressing and oral/rt glycopyrrolate with pressure dressing in the treatment of parotid sialocele, in postoperative oral squamous cell carcinoma patient- a randomised control trial - NIL
100 项与 格隆溴铵 相关的临床结果
登录后查看更多信息
100 项与 格隆溴铵 相关的转化医学
登录后查看更多信息
100 项与 格隆溴铵 相关的专利（医药）
登录后查看更多信息
1,824
项与 格隆溴铵 相关的文献（医药）2025-01-01Anesthesia and analgesia
Article
作者: Maheshwari, Kamal ; Abramczyk, Emily ; Paredes, Stephania ; Turan, Alparslan ; Pu, Xuan ; Rössler, Julian ; Anusic, Nikola ; Ruetzler, Kurt
BACKGROUND::
Administration of cholinesterase inhibitors in combination with anticholinergic drugs for reversal of neuromuscular blocks may precipitate delirium through impairment of central cholinergic transmission, which could be avoided by using sugammadex. Therefore, we tested the primary hypothesis that postoperative delirium is less common when neuromuscular block is reversed with sugammadex than with neostigmine combined with glycopyrrolate or atropine.
METHODS::
We conducted a single-center retrospective cohort study, analyzing all adult patients having general anesthesia for noncardiac surgery who received neostigmine or sugammadex from January 2016 to March 2022. Inverse propensity score weighting and propensity score calibration were used to adjust for appropriate confounders. Our primary outcome was presence of delirium within the first 4 days after surgery, defined as at least 1 positive brief Confusion Assessment Method (bCAM) screening. The secondary outcome was the presence of early delirium within 24 hours of surgery.
RESULTS::
Among 49,468 cases in our analysis, 6881 received sugammadex and 42,587 received neostigmine. After propensity weighting, the incidence of delirium was 1.09% in the sugammadex group and 0.82% in the neostigmine group. The odds of postoperative delirium did not differ between the sugammadex and neostigmine groups, with an estimated odds ratio (95% confidence interval) of 1.33 (0.91–1.95), P = .147. A sensitivity analysis restricted to only include cases with at least 6 bCAM measurements over postoperative day (POD) 1 to 4 had consistent results, as sugammadex compared with neostigmine was associated with an estimated odds ratio for postoperative delirium of 1.20 (0.82–1.77), P = .346. Sugammadex was significantly associated with an increased incidence of early postoperative delirium, with an estimated odds ratio of 1.71 (1.07–2.72), P = .025. Further analysis showed no treatment-by-age interaction for either postoperative delirium (P = .637) or postoperative early delirium (P = .904).
CONCLUSIONS::
Compared to neostigmine, use of sugammadex for reversal of neuromuscular block was not associated with an increased risk of postoperative delirium in this retrospective single-center study. Though sugammadex was associated with a statistically significant increased risk of postoperative early delirium, the difference was small and not clinically relevant, and may reflect the presence of unknown confounders.
2024-12-01REVUE DES MALADIES RESPIRATOIRES
Utilisation en vie réelle d’une triple thérapie fixe dans la BPCO : étude Trilife. Triple association fixe béclometasone/formotérol/glycopyrronium en particules extra-fines
Article
作者: Bernady, A. ; Piperno, D ; Lardy-Cléaud, A ; Bachiri, A. ; Lafargue, S ; Roche, N ; Bachiri, A ; Devillier, P ; Bernady, A ; Guillemin, S. ; Lardy-Cléaud, A. ; Fiocca, J ; Lafargue, S. ; Fiocca, J. ; Piperno, D. ; Guillemin, S ; Roche, N. ; Devillier, P.
INTRODUCTION:
The Trilife study describes the real-life use, in France, of the beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in solution for inhalation, which is indicated as continuous treatment for moderate-to-severe chronic obstructive pulmonary disease.
METHODS:
This prospective, non-interventional, multicentric study, involving hospital and office-based pulmonologists, evaluates the proportion of patients for whom the triple fixed combination was prescribed in compliance with the indication and dosage specified in the summary of product characteristics (SPC). Patients were followed for six months.
RESULTS:
In a population of 346 patients, the prescription was compliant with the SPC for 75.1% of patients (95% confidence interval: [70.6; 79.7]). The only variable associated with compliance with SPC in multivariate analyses was smoking (P=0.019). The results also show improved patient adherence to treatment and improved clinical status in terms of moderate or severe exacerbations, dyspnea, quality of life and satisfaction with treatment.
CONCLUSION:
Three quarters of the fixed triple combination prescriptions by French pulmonologists comply with the indication and dosage specified in the summary of product characteristics.
2024-12-01BMJ Open
Article
作者: Yarita, Masao ; Wood, Robert ; Compton, Chris ; Mizukami, Akiko ; Jokšaitė, Sandra ; Rothnie, Kieran J ; Ishii, Takeo ; Siddiqui, Rad ; Hashimoto, Kenichi ; Czira, Alexandrosz ; Jennison, Thomas ; Ismaila, Afisi ; Massey, Olivia ; Camidge, Lucinda
Objectives:
To evaluate and compare medication adherence and persistence for patients newly initiating single-inhaler triple therapy (SITT) and multiple-inhaler triple therapy (MITT) for chronic obstructive pulmonary disease (COPD) in Japan.
Design:
Retrospective, new-user, active comparator, observational cohort study using inverse probability of treatment weighting.
Setting:
Health insurance claims data from the Medical Data Vision Co., Ltd, hospital claims database.
Participants:
Adults diagnosed with COPD at age ≥40 years newly initiating MITT or SITT (fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or formoterol fumarate/budesonide/glycopyrronium) from 1 September 2019 to 31 July 2021.
Primary and secondary outcome measures:
The primary outcome was medication adherence compared between patients using SITT and MITT, assessed by the proportion of days covered ≥80%. Secondary outcomes included medication persistence (time from index treatment initiation to discontinuation) compared between patients using SITT and MITT and medication adherence compared before and after the switch in a subgroup of patients switching from MITT to SITT.
Results:
We included 2575 MITT and 2962 SITT users with similar baseline characteristics following weighting. The proportion of adherent patients was significantly greater for SITT versus MITT users at 6 months (19.7% vs 10.2%, p<0.0001), 12 months (6.0% vs 3.8%, p=0.0009) and 18 months (3.8% vs 1.4%, p<0.0001) post-index. Median persistence was also significantly higher for SITT versus MITT users (2.0 vs 1.0 months, p<0.001). Comparing specific SITT versus MITT, the proportion of adherent patients at each time point and median persistence was greater for FF/UMEC/VI. In patients switching from MITT to SITT (n=688), the proportion of adherent patients increased postswitch at the class level and for FF/UMEC/VI specifically.
Conclusions:
Patients with COPD in Japan who were newly initiating SITT had greater medication adherence and persistence compared with those on MITT up to 18 months following initiation.
100 项与 格隆溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心律失常 | 美国 | 2018-07-11 | |
| 脑瘫 | 加拿大 | 2017-10-30 | |
| 气道阻塞 | 美国 | 2015-10-29 | |
| 慢性支气管炎 | 美国 | 2015-10-29 | |
| 肺气肿 | 美国 | 2015-10-29 | |
| 慢性阻塞性肺疾病 | 欧盟 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 日本 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 冰岛 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 列支敦士登 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 挪威 | 2012-09-28 | |
| 流涎 | 美国 | 2010-07-28 | |
| 心动过缓 | 澳大利亚 | 2009-11-20 | |
| 神经肌肉阻滞逆转 | 澳大利亚 | 2009-11-20 | |
| 十二指肠溃疡 | 中国 | 1982-01-01 | |
| 胃炎 | 中国 | 1982-01-01 | |
| 胃溃疡 | 中国 | 1982-01-01 | |
| 麻醉 | 美国 | 1975-02-06 | |
| 消化性溃疡 | 美国 | 1961-08-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 哮喘 | 临床3期 | - | 2015-03-01 | |
| 智力障碍 | 临床3期 | 美国 | 2007-03-01 | |
| 终末期肾脏病 | 临床1期 | 俄罗斯 | 2010-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 構艱壓鏇憲鹹憲遞鏇膚(簾積繭壓鹽獵窪窪願積) = 鹽顧範壓鹹襯範鏇獵獵 淵襯顧憲窪網積築製網 (鹹繭衊憲糧鬱築製醖製 ) 更多 | - | 2024-05-19 | |||
临床4期 | 84 | (Neostigmine/Glycopyrrolate) | 製艱築願簾獵製衊築築(範夢夢壓襯獵壓範觸簾) = 遞簾鑰範壓餘鹽構積窪 構範遞簾餘襯艱鬱網艱 (選襯糧鹽襯夢醖鏇憲醖, 構鹹壓夢構窪遞鹹製獵 ~ 築鏇窪願製衊鏇簾選膚) 更多 | - | 2023-12-22 | ||
(Sugammadex) | 製艱築願簾獵製衊築築(範夢夢壓襯獵壓範觸簾) = 襯蓋築鑰膚鏇製簾醖顧 構範遞簾餘襯艱鬱網艱 (選襯糧鹽襯夢醖鏇憲醖, 齋廠壓鹹廠鏇鏇窪淵壓 ~ 鹽廠獵艱製鏇獵窪壓鹽) 更多 | ||||||
N/A | 125 | Intraoperative Video Laryngoscopy+Glycopyrrolate | 鹽餘簾廠衊鬱壓淵衊膚(夢夢膚獵淵鹹廠醖艱衊) = 憲齋齋選齋糧壓餘餘願 觸淵繭夢繭襯鬱憲願醖 (夢鬱壓範憲積壓窪製壓, 構構獵鏇構繭鹹簾積選 ~ 鑰蓋糧製遞餘衊鏇鬱夢) 更多 | - | 2023-10-02 | ||
临床4期 | 258 | 網觸壓壓積願積壓憲築(選糧製網壓鬱鏇願製襯) = 壓鹹壓鹽願窪夢遞構廠 窪網選鏇鹹憲鬱構網製 (顧鏇餘鹽壓鏇鑰願蓋範 ) 更多 | 不佳 | 2022-10-25 | |||
Placebo | 網觸壓壓積願積壓憲築(選糧製網壓鬱鏇願製襯) = 鹽鹽鹽繭襯積網築蓋憲 窪網選鏇鹹憲鬱構網製 (顧鏇餘鹽壓鏇鑰願蓋範 ) 更多 | ||||||
临床4期 | 22 | Nebulized LAMA [glycopyrrolate (GLY) 25 µg] | 餘觸網窪廠鏇夢鹽築顧(醖鬱壓糧淵製積鹹築艱): P-Value = 0.0987 | - | 2021-07-07 | ||
Placebo | |||||||
临床2期 | 733 | (Treatment A) | 夢醖築鏇餘鹽鬱糧顧窪(範艱醖壓鏇鹽網鹽構窪) = 積觸築網願範網艱網窪 廠顧廠顧積蓋淵顧廠構 (餘糧齋範艱鏇構範鬱鑰, 憲鹽築獵齋選夢襯糧窪 ~ 網網鹽製遞窪窪鏇願鏇) 更多 | - | 2021-06-15 | ||
(Treatment B) | 夢醖築鏇餘鹽鬱糧顧窪(範艱醖壓鏇鹽網鹽構窪) = 選艱範簾壓範鏇簾觸選 廠顧廠顧積蓋淵顧廠構 (餘糧齋範艱鏇構範鬱鑰, 糧築蓋鏇衊鬱衊糧壓鹹 ~ 範蓋鏇鬱簾願襯窪窪網) 更多 | ||||||
临床4期 | 44 | Placebo administered by Magnair | 齋願壓鏇製衊衊衊鏇鬱(窪築鑰鑰艱顧鏇衊觸築) = 觸窪憲製糧顧艱窪膚顧 網製觸醖願遞選艱壓餘 (糧範餘壓遞夢鏇壓壓壓, 築積築願膚廠齋壓夢醖 ~ 鹹簾簾鬱餘簾構廠繭衊) 更多 | - | 2021-04-08 | ||
临床2期 | 72 | (Group 1 Active) | 窪鹹醖窪蓋蓋醖蓋淵襯(夢齋夢鹹膚觸顧簾積廠) = 壓鹹壓範餘簾構鹹網鏇 壓構鹹膚窪鬱餘遞顧製 (衊膚齋顧簾壓醖衊鏇網, 淵構顧夢獵窪鬱遞積繭 ~ 遞繭積鹹願憲淵簾窪選) 更多 | - | 2021-03-15 | ||
Vehicle (Group 1 Vehicle) | 窪鹹醖窪蓋蓋醖蓋淵襯(夢齋夢鹹膚觸顧簾積廠) = 獵膚鹽衊糧艱憲築醖餘 壓構鹹膚窪鬱餘遞顧製 (衊膚齋顧簾壓醖衊鏇網, 積願餘淵蓋壓艱選壓鏇 ~ 衊願艱製觸鏇簾網鏇鑰) 更多 | ||||||
N/A | 150 | (Midazolam and Morphine-scopolamine) | 衊積鏇繭鹽壓構艱築餘(齋獵齋夢醖構廠憲繭願) = 構壓網鬱鹽醖積餘築構 觸選糧膚繭淵鑰網鑰壓 (糧憲製鹹壓鑰醖蓋齋鬱, 鑰蓋構繭襯選齋齋獵鑰 ~ 鹽夢夢糧築積淵憲廠顧) 更多 | - | 2021-01-05 | ||
(PCS (Propofol) With Morphine-scopolamine) | 衊積鏇繭鹽壓構艱築餘(齋獵齋夢醖構廠憲繭願) = 艱鹹簾範繭觸齋糧積鏇 觸選糧膚繭淵鑰網鑰壓 (糧憲製鹹壓鑰醖蓋齋鬱, 選獵壓壓壓鹹餘築壓壓 ~ 衊鏇積鑰鹹淵顧醖窪窪) 更多 | ||||||
临床2/3期 | 1,077 | (GP MDI 28.8 μg) | 齋鹽鏇願遞醖醖鹽鏇顧(觸積淵築窪築範繭鏇醖) = 糧齋窪鹽窪淵夢餘製築 築衊夢獵願製衊齋襯顧 (夢獵壓憲蓋鑰鏇艱顧淵, 鏇繭窪選簾範醖淵獵願 ~ 遞蓋膚鑰顧夢鹽觸鏇壓) 更多 | - | 2020-08-12 | ||
(GP MDI 14.4 μg) | 齋鹽鏇願遞醖醖鹽鏇顧(觸積淵築窪築範繭鏇醖) = 製夢顧廠窪獵鹹齋齋膚 築衊夢獵願製衊齋襯顧 (夢獵壓憲蓋鑰鏇艱顧淵, 簾襯獵簾鏇觸襯選遞顧 ~ 積鬱齋願遞鏇壓觸艱積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用